🔍

INDIAGLYCO - India Glycols

📊 NSE: INDIAGLYCO 🏢 Breweries & Distilleries 📅 Last Updated: 12/14/2025 7:57

📢 Recent Corporate Announcements

India Glycols: ₹191.76 Cr Fine Set Aside; Penalty Reduced to ₹41 Cr in Customs Case

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 13 Mar 2026, 08:04 PM

India Glycols Limited has received a favorable appellate order regarding a customs duty dispute from March 2024. The Appellate Authority has set aside a massive redemption fine of ₹191.76 crore and reduced the penalty from ₹82 crore to ₹41 crore. While the core duty demand of ₹33.43 crore plus interest remains upheld, the total potential liability has decreased significantly. The company intends to file a second appeal to contest the remaining confirmed amounts.

Redemption fine of ₹191.76 crore has been completely set aside by the Appellate Authority.
Penalty amount reduced by 50%, from ₹82 crore down to ₹41 crore.
Customs duty demand of ₹33.43 crore plus applicable interest remains upheld.
Company plans to file a second appeal against the remaining ₹74.43 crore (duty + penalty) plus interest.

💡 Investors should view this as a positive development as it significantly reduces a major contingent liability, though the remaining ₹74.43 crore plus interest should still be monitored through the next appeal phase.

CARE Places India Glycols on Rating Watch with Developing Implications Amid Demerger Plans

🔵 WATCH ⭐ 8/10

REGULATORY 📅 10 Mar 2026, 06:57 PM

CARE Ratings has placed India Glycols' 'CARE A-' long-term rating on 'Rating Watch with Developing Implications' due to the proposed demerger of its Biofuel, Potable Spirits, and Bio-pharma businesses. The company's financial profile is improving, supported by a ₹467 crore preferential issue in Q3FY26 which was primarily used for debt reduction. Performance for 9MFY26 shows 11% revenue growth to ₹3,239 crore with margins expanding to 15.04%. The restructuring is expected to be completed within six months, resulting in three separate entities to enhance management focus.

CARE A- rating placed on 'Rating Watch with Developing Implications' following the board-approved composite scheme of arrangement.
Raised ₹467 crore via preferential issue in Q3FY26, reducing total debt including LC acceptances to ₹1,793 crore as of January 2026.
9MFY26 revenue grew 11% YoY to ₹3,239 crore with PBILDT margins expanding significantly to 15.04%.
Net debt to PBILDT ratio is projected to improve to 2.5x-3.0x by FY26-end from 4.31x in FY25.
Demerger will split operations into IGL (Chemicals), IGL Spirits (Biofuels/Spirits), and Ennature Bio Pharma (Nutraceuticals).

💡 Investors should maintain a watch on the NCLT approval process for the demerger, which is expected to unlock value across different business segments. The substantial debt reduction and improving margins provide a positive cushion during this transition period.

India Glycols Board to Meet on March 17 to Consider Interim Dividend for FY 2025-26

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 10 Mar 2026, 04:50 PM

India Glycols Limited has scheduled a Board of Directors meeting on March 17, 2026, to consider the declaration of an interim dividend for the financial year 2025-26. Following this announcement, the company has implemented a trading window closure for insiders from March 11 to March 19, 2026. This move indicates a potential cash payout to shareholders, reflecting the company's current financial health and commitment to returning value. Investors should watch for the specific dividend amount and record date following the meeting.

Board meeting scheduled for March 17, 2026, to consider interim dividend for FY 2025-26
Trading window for securities closed from March 11, 2026, to March 19, 2026
Meeting convened under Regulation 29 of SEBI (LODR) Regulations, 2015
The outcome of the meeting will determine the dividend payout ratio for the current fiscal year

💡 Investors should monitor the March 17 board meeting outcome for the dividend amount and record date to assess the yield. Existing shareholders may benefit from the potential payout, while new investors should evaluate the stock's valuation relative to the dividend.

India Glycols Schedules NCLT-Convened Creditors Meeting for Demerger on March 24, 2026

🟡 NEUTRAL ⭐ 7/10

M&A 📅 20 Feb 2026, 02:46 PM

India Glycols Limited (IGL) is progressing with its corporate restructuring plan to demerge businesses into Ennature Biopharma Limited and IGL Spirits Limited. Following orders from the NCLT Allahabad Bench, the company has scheduled a meeting of its unsecured creditors on March 24, 2026, to seek approval for the Scheme of Arrangement. This follows similar procedural steps for shareholders and is a mandatory regulatory requirement for the demerger to proceed. The remote e-voting for eligible creditors is set to take place between March 20 and March 23, 2026.

NCLT-convened meeting of unsecured creditors scheduled for March 24, 2026, via Video Conferencing.
Scheme involves the demerger of units into two resulting companies: Ennature Biopharma Limited and IGL Spirits Limited.
Remote e-voting period is set from March 20, 2026 (9:00 AM) to March 23, 2026 (5:00 PM).
The cut-off date for determining the eligibility of unsecured creditors to vote was November 15, 2025.

💡 Investors should track the outcome of these meetings as the demerger will lead to the creation of specialized entities for biopharma and spirits. No immediate action is required, but the restructuring is a key milestone for potential value unlocking.

India Glycols Schedules NCLT-Convened Meeting on March 24, 2026, for Business Demerger

🟢 POSITIVE ⭐ 9/10

M&A 📅 20 Feb 2026, 02:33 PM

India Glycols Limited (IGL) has announced a Court Convened Meeting on March 24, 2026, to seek shareholder approval for a major Scheme of Arrangement. The plan involves demerging specific business undertakings into two new entities: Ennature Biopharma Limited and IGL Spirits Limited. Shareholders as of the cut-off date of March 17, 2026, will be eligible to vote on the proposal. This restructuring is intended to streamline operations and potentially unlock value for shareholders by creating focused business units.

NCLT-convened meeting for equity shareholders scheduled for March 24, 2026, at 11:00 A.M. via video conferencing.
Proposed demerger of business segments into Ennature Biopharma Limited and IGL Spirits Limited.
Remote e-voting period is set from March 20, 2026, to March 23, 2026, with a cut-off date of March 17, 2026.
The scheme has already received 'No-objection' from NSE and 'No adverse observation' from BSE as of November 2025.
Special purpose financial statements for the period ending September 30, 2025, have been prepared for all involved entities.

💡 Investors should monitor the demerger ratio and the specific assets being transferred to evaluate the long-term value of the new entities. Shareholders are advised to participate in the e-voting process to support the corporate restructuring.

India Glycols Reschedules NCLT-Directed Shareholder Meeting to March 24, 2026

🟡 NEUTRAL ⭐ 6/10

M&A 📅 18 Feb 2026, 04:35 PM

India Glycols Limited has received a revised order from the NCLT Allahabad Bench regarding its proposed Scheme of Arrangement involving Ennature Biopharma and IGL Spirits. The meetings for equity shareholders and unsecured creditors, originally set for March 9, 2026, have been rescheduled to March 24, 2026. This administrative change was necessitated by the unavailability of the NCLT-appointed Chairperson on the original date. The meetings will be conducted via video conferencing to consider and approve the restructuring scheme.

NCLT Allahabad Bench approved rescheduling of shareholder and creditor meetings to March 24, 2026.
The original meeting date was March 9, 2026, but was changed due to the Chairperson's unavailability.
The Scheme of Arrangement involves India Glycols, Ennature Biopharma Limited, and IGL Spirits Limited.
Meetings will be held via video conferencing under Sections 230 to 232 of the Companies Act, 2013.
The rest of the NCLT order dated January 15, 2026, remains unchanged and valid.

💡 Investors should mark the new date of March 24, 2026, to participate in the voting process for the proposed demerger and arrangement. This is a routine administrative delay and does not reflect on the merits of the underlying transaction.

India Glycols Releases Audio Recording of Q3 & 9MFY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 12 Feb 2026, 06:49 PM

India Glycols Limited has made the audio recording of its Q3 and 9MFY26 earnings conference call available to the public. The call, which took place on February 12, 2026, discussed the company's financial performance for the quarter and nine-month period ending December 2025. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations, 2015. Investors can access the full recording via the company's website to hear management's detailed commentary on business operations.

Audio recording of the Q3 & 9MFY26 earnings call held on February 12, 2026, is now live.
The recording covers management's perspective on the financial results for the nine-month period of FY26.
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Direct link to the MP3 file has been provided for investor transparency and access.

💡 Investors should listen to the recording to understand management's outlook on the bio-based chemicals and potable spirits segments. Focus on commentary regarding raw material price volatility and margin expectations for Q4 FY26.

India Glycols Q3FY26 Net Profit Rises 19% to ₹68 Cr; EBITDA Margins Expand to 16%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 03:40 PM

India Glycols reported a strong Q3FY26 with net revenue growing 13% YoY to ₹1,102 crore and EBITDA surging 36% to ₹176 crore. The company achieved a significant debt reduction of ₹582 crore, primarily through a preferential allotment, which is expected to lower interest costs significantly from Q4 onwards. Segmental performance was robust, particularly in Bio-Fuels where revenue jumped 45% and Bio-Based Specialties where EBIT margins expanded to 12.8%. The Potable Spirits division continues its premiumization strategy through the Amrut partnership and expansion into new markets like Kerala and CSD.

Consolidated Net Revenue for Q3FY26 grew 13% YoY to ₹1,102 Cr, while 9M PAT rose 23.4% to ₹206 Cr.
EBITDA margins expanded by 277 bps YoY to 16.0% in Q3, driven by operational efficiencies and high-margin product focus.
Total debt reduced by ₹582 Cr (₹467 Cr via preferential allotment), which will significantly reduce finance costs in future quarters.
Bio-Fuel segment revenue surged 45.2% YoY to ₹394 Cr in Q3, supported by India's 20% ethanol blending target.
Potable Spirits segment achieved 9M revenue of ₹1,025 Cr with a healthy EBIT margin of 21.2%.

💡 Investors should note the substantial debt reduction and margin expansion as key drivers for future profitability. The company's strategic shift toward premium spirits and high-margin specialty chemicals makes it a strong candidate for long-term growth.

India Glycols Appoints Rakesh Kumar Srivastava as Head Operations (Dehradun)

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 10 Feb 2026, 05:23 PM

India Glycols Limited has appointed Shri Rakesh Kumar Srivastava as Head Operations for its Dehradun facility, effective February 10, 2026. Mr. Srivastava joins as a Senior Management Personnel, bringing over 29 years of extensive experience in the pharmaceutical and chemical industries. He previously held the position of General Manager – Production at Mangalam Drugs & Organic Limited. This appointment is intended to strengthen the operational leadership at one of the company's key manufacturing locations.

Shri Rakesh Kumar Srivastava appointed as Head Operations (Dehradun) effective February 10, 2026.
Brings over 29 years of professional experience in the chemical and pharmaceutical sectors.
Previously associated with Mangalam Drugs & Organic Limited as General Manager – Production.
Holds a Master's degree in Organic Chemistry and a Bachelor's in Chemistry.

💡 This is a routine senior management appointment and does not necessitate any immediate change in investment strategy. Investors should monitor the company's upcoming quarterly results for operational improvements at the Dehradun site.

India Glycols Q3 PAT Jumps 49% YoY to ₹65.26 Cr; Bio-Fuel Segment Revenue Grows 45%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 05:21 PM

India Glycols Limited (IGL) reported a robust performance for Q3 FY26, with standalone Net Profit rising 48.8% YoY to ₹65.26 crore. Revenue from operations increased 5.25% YoY to ₹2,551.06 crore, significantly supported by a 45% surge in the Bio-Fuel segment revenue. The company is actively pursuing a demerger of its Bio Pharma and Spirits & Biofuel undertakings into separate listed entities, with an appointed date of April 1, 2026. Furthermore, IGL strengthened its capital base by raising approximately ₹467 crore through a preferential allotment at ₹915 per share during the quarter.

Standalone Net Profit (PAT) grew 48.8% YoY to ₹65.26 crore vs ₹43.84 crore in the previous year.
Bio-Fuel segment revenue surged 45% YoY to ₹394.28 crore from ₹271.54 crore.
Profit Before Tax (PBT) increased 51% YoY to ₹88.30 crore despite a ₹0.83 crore exceptional charge related to new labour codes.
Completed a preferential allotment of 51.03 lakh shares at ₹915 per share, raising ₹466.99 crore.
The demerger process is on track with the NCLT Allahabad Bench allowing the first motion application on January 15, 2026.

💡 Investors should monitor the upcoming demerger as a major value-unlocking event and track the continued high growth in the Bio-Fuel segment. The recent fundraise at ₹915 per share indicates strong institutional confidence and provides a valuation benchmark for the current market price.

India Glycols Schedules Q3 & 9MFY26 Earnings Conference Call for February 12, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Feb 2026, 06:31 PM

India Glycols Limited has announced that it will hold its earnings conference call to discuss Q3 and 9MFY26 financial results on February 12, 2026, at 16:00 IST. The call will feature key leadership including the CEO, CFO, and the Head of the Liquor Business. This routine disclosure allows investors to engage with management regarding the company's recent performance and future strategy. The event is coordinated by InCred Equities and includes international dial-in options for global investors.

Earnings conference call for Q3 & 9MFY26 scheduled for February 12, 2026, at 4:00 PM IST.
Key management participants include CEO Rupark Sarswat and CFO Anand Singhal.
The session will specifically address financial results for the quarter and nine-month period ending December 2025.
Universal dial-in numbers provided are +91 22 6280 1527 and +91 22 7115 8322.

💡 Investors should mark the date to listen for management commentary on segment margins and the growth outlook for the liquor business. No immediate trading action is required based on this scheduling announcement.

India Glycols Schedules Q3 & 9MFY26 Earnings Conference Call for February 12, 2026

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 03 Feb 2026, 06:27 PM

India Glycols Limited has announced its earnings conference call to discuss financial results for the third quarter and nine months ended December 31, 2025. The call is scheduled for Thursday, February 12, 2026, at 16:00 IST. Senior management, including the CEO, CFO, and Head of the Liquor Business, will be present to address investor queries. This is a routine regulatory disclosure providing a platform for stakeholders to understand the company's recent performance and future strategy.

Earnings conference call for Q3 & 9MFY26 scheduled for February 12, 2026, at 4:00 PM IST.
Key participants include CEO Rupark Sarswat, CFO Anand Singhal, and Liquor Business Head S.K. Shukla.
The call will be hosted in coordination with InCred Equities.
Universal dial-in numbers are +91 22 6280 1527 and +91 22 7115 8322.
DiamondPass registration is available for express entry to the call.

💡 Investors should attend the call or review the transcript to understand the performance of the liquor and chemical segments. Focus on management commentary regarding margin pressures and the growth outlook for the remainder of FY26.

India Glycols Board Meeting on Feb 10, 2026, to Approve Q3 FY26 Financial Results

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 03 Feb 2026, 05:12 PM

India Glycols Limited has scheduled a Board of Directors meeting for February 10, 2026, to review and approve the unaudited financial results for the quarter and nine months ending December 31, 2025. In compliance with SEBI insider trading regulations, the trading window for company securities has been closed since January 1, 2026. The window is set to reopen after February 12, 2026, following the results announcement. This is a routine regulatory filing ahead of the quarterly earnings release.

Board meeting scheduled for February 10, 2026, to approve Q3 and nine-month financial results.
Results to be reviewed for the period ending December 31, 2025, on both standalone and consolidated bases.
Trading window for insiders remains closed from January 1, 2026, until February 12, 2026.

💡 Investors should monitor the upcoming results on February 10 to evaluate the company's operational performance and segment-wise growth. No immediate trading action is required based on this routine scheduling announcement.

India Glycols Receives NCLT Approval for First Motion of Three-Way Demerger Scheme

🟢 POSITIVE ⭐ 9/10

M&A 📅 16 Jan 2026, 03:46 PM

India Glycols Limited has received NCLT approval for the first motion of its scheme to demerge its 'Bio Pharma' and 'Spirits and Biofuel' undertakings into two separate entities, Ennature Biopharma and IGL Spirits. The NCLT has ordered meetings for equity shareholders and unsecured creditors while dispensing with meetings for secured creditors who provided 95.46% consent. Both resulting companies are intended to be listed on the NSE and BSE, aiming to unlock value and provide management focus for each distinct business segment. The appointed date for this restructuring is set for April 1, 2026.

NCLT Allahabad Bench allowed the first motion for demerging Bio Pharma and Spirits & Biofuel units.
Secured creditors' meeting dispensed with after obtaining 95.46% consent in value.
Resulting entities, Ennature Biopharma and IGL Spirits, are planned to be listed on NSE and BSE.
The appointed date for the proposed Scheme of Arrangement is set as April 1, 2026.
Equity shareholders of resulting companies provided 99.94% consent, leading to meeting dispensation.

💡 Investors should maintain a positive outlook as the demerger is likely to unlock value by creating specialized, listed entities for the biopharma and spirits businesses. Monitor the upcoming shareholder and creditor meetings for the final approval stages.

India Glycols Submits SEBI Compliance Certificate for Q3 FY2025-26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 03:43 PM

India Glycols Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document confirms that for the quarter ended December 31, 2025, all securities received for dematerialization were processed within 15 days. The Registrar, MCS Share Transfer Agent Limited, verified that physical certificates were mutilated and cancelled as per regulations. This filing is a standard administrative requirement for listed companies in India to ensure the integrity of electronic shareholding.

Quarterly compliance certificate submitted for the period ending December 31, 2025.
Dematerialization requests were completed within the mandatory 15-day window.
Physical share certificates were verified, mutilated, and cancelled by the RTA.
The filing ensures the company's adherence to SEBI (Depositories and Participants) Regulations.

💡 This is a routine administrative update with no impact on stock valuation or business operations. No specific action is required from shareholders.

View All INDIAGLYCO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Biofuels (BF) grew 54.5% YoY to INR 770 Cr in H1FY26. Potable Spirits (PS) grew 24.5% YoY to INR 338 Cr in Q2FY26. Bio-based Specialities and Performance Chemicals (BSPC) declined 22.8% YoY to INR 588 Cr in H1FY26 due to subdued pricing and demand in Chinese/SE Asian markets.

Geographic Revenue Split

Not disclosed in available documents, though the company notes management decisions to restrict supply to domestic markets due to subdued pricing in Chinese and South-East Asian markets.

Profitability Margins

Gross Revenue reached INR 9,052 Cr in FY25, up 13.9% from INR 7,944 Cr in FY24. PAT margin improved to 6.5% in H1FY26 from 5.7% in H1FY25. Net profit for FY25 was INR 180 Cr compared to INR 152 Cr in FY24, a 18.4% increase.

EBITDA Margin

EBITDA margin stood at 14.6% in H1FY26, expanding by 172 bps from 12.8% in H1FY25. Absolute EBITDA grew 25.1% YoY to INR 311 Cr. The company has seen a steady margin recovery from 11% in FY22 to nearly 15% in FY26.

Capital Expenditure

Planned capex of INR 175 Cr and INR 190 Cr for FY25 and FY26 respectively, primarily funded through term loans for distillery capacity enhancement and the New Specialities Unit (NSU). Gross Fixed Assets increased to INR 4,377 Cr in FY25 from INR 3,713 Cr in FY24.

Credit Rating & Borrowing

Credit rating maintained by CARE Ratings with an 'Adequate' liquidity profile. Interest coverage ratio was 3.15x in 9MFY25. Finance costs increased 23.7% YoY to INR 94 Cr in H1FY26 due to higher debt for capex.

⚙️ Operational Drivers

Raw Materials

Ethyl Alcohol (primary feedstock for BSPC), Grain/Molasses (for distillery), and various chemicals. Raw material costs are highly volatile and impact the spread for glycol products.

Import Sources

Sourced domestically within India, particularly from states like Uttar Pradesh and Uttarakhand for distillery operations.

Capacity Expansion

Distillery capacity is being enhanced with a capex of INR 365 Cr over two years. The New Specialities Unit (NSU) is currently ramping up operations as of Q2FY26 to drive future revenue.

Raw Material Costs

BSPC segment profitability is susceptible to the spread between glycol products and ethyl alcohol. PS segment margins were previously impacted by sharp escalations in ethanol and material costs.

Manufacturing Efficiency

EBITDA margin expansion of 216 bps in Q2FY26 indicates improved operational efficiency and better product mix.

📈 Strategic Growth

Expected Growth Rate

11-14%

Growth Strategy

Scaling up distillery facilities to supply ethanol to Oil Marketing Companies (OMCs), ramping up the New Specialities Unit (NSU), and expanding the Potable Spirits portfolio with in-house brands. The company is also leveraging its JV with Clariant for bio-based specialities.

Products & Services

Bio-based glycols, Ethanol (for OMCs), Country Liquor, IMFL (Spirits), Industrial Gases, Sugar, and Nutraceuticals (Ennature Biopharma).

Brand Portfolio

Zumba Lemoni, Soulmate Blu, Amazing Vodka (Potable Spirits).

New Products/Services

Launched in-house brands Zumba Lemoni and Soulmate Blu; planning to launch a new Brandy brand to strengthen the Potable Spirits segment.

Market Expansion

Strengthening footprint in the Paramilitary business and institutional channels for Potable Spirits.

Strategic Alliances

Joint Venture with Clariant (Clariant IGL) which contributed INR 30 Cr to PAT in H1FY26, a 40.1% YoY increase.

🌍 External Factors

Industry Trends

The Indian chemical industry is expected to grow to USD 300 billion by 2025. The liquor industry shows strong potential with volumes of 350 million cases, while the government's ethanol blending mandate is driving the Biofuel segment.

Competitive Landscape

Competes with traditional petrochemical-based glycol producers and other distillery-based chemical companies in India.

Competitive Moat

Moat is built on green technology-based manufacturing (bio-based vs petro-based) and a strong market position in the regulated liquor industry in North India. Sustainability is driven by the global shift toward renewable chemicals.

Macro Economic Sensitivity

Highly sensitive to global chemical cycles and crude oil prices which affect substitute glycol pricing.

Consumer Behavior

Shift toward premiumization in the Potable Spirits segment and increasing demand for sustainable/green chemicals in global supply chains.

Geopolitical Risks

Trade tensions and global supply chain shifts (China+1) are benefiting the Indian chemical sector, though subdued demand in China currently pressures export volumes.

⚖️ Regulatory & Governance

Industry Regulations

Highly regulated liquor industry where states control production, sales, and duty structures. Ethanol prices for OMCs are also subject to government mandates.

Environmental Compliance

Focus on green technology-based chemicals; specific ESG costs not disclosed.

Taxation Policy Impact

Tax expenses for H1FY26 were INR 36 Cr on a PBT of INR 174 Cr, representing an effective tax rate of approximately 20.7%.

⚠️ Risk Analysis

Key Uncertainties

Volatility in the spread between ethyl alcohol and glycol prices; potential introduction of prohibition laws in key states; and the successful ramp-up of the NSU unit.